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Abstract
Summary Odanacatib is a cathepsin K inhibitor investigated
for the treatment of postmenopausal osteoporosis. Phase 2
data indicate that 50 mg once weekly inhibits bone resorption
and increases bone mineral density, with only a transient
decrease in bone formation. We describe the background,
design and participant characteristics for the phase 3 registra-
tion trial.
Introduction Odanacatib (ODN) is a selective cathepsin K
inhibitor being evaluated for the treatment of osteoporosis.
In a phase 2 trial, ODN 50 mg once weekly reduced bone
resorption while preserving bone formation and progressively
increased BMD over 5 years. We describe the phase III Long-
Term ODN Fracture Trial (LOFT), an event-driven,
randomized, blinded placebo-controlled trial, with preplanned
interim analyses to permit early termination if significant
fracture risk reduction was demonstrated. An extension was
planned, with participants remaining on their randomized
treatment for up to 5 years, then transitioning to open-label
ODN.
Methods The three primary outcomes were radiologically
determined vertebral, hip, and clinical non-vertebral fractures.
Secondary end points included clinical vertebral fractures,
BMD, bone turnover markers, and safety and tolerability,
including bone histology. Participants were women, 65 years
or older, with a BMD T-score ≤−2.5 at the total hip (TH) or
femoral neck (FN) or with a prior radiographic vertebral
fracture and a T-score ≤−1.5 at the TH or FN. They were
This study was registered with clinicaltrials.gov with registration number
NCT00529373.
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randomized to ODN or placebo tablets. All received weekly
vitamin D3 (5600 international units (IU)) and daily calcium
supplements as needed to ensure a daily intake of approxi-
mately 1200 mg.
Results Altogether, 16,713 participants were randomized at
387 centers. After a planned interim analysis, an independent
data monitoring committee recommended that the study be
stopped early due to robust efficacy and a favorable benefit/
risk profile. Following the base study closeout, 8256 partici-
pants entered the study extension.
Conclusions This report details the background and study
design of this fracture end point trial and describes the baseline
characteristics of its participants.
Keywords Cathepsin K . Fracture . Odanacatib .
Osteoporosis . Postmenopausal
Introduction
Osteoporosis is a metabolic bone disease characterized by a
chronic excess of bone resorption relative to bone formation,
leading to progressive bone loss, deterioration of bone
microarchitecture, and increased risk of fracture [1].
Bone formation and resorption are tightly coordinated dur-
ing the remodel ing cycle . Osteocytes exhibi t a
mechanosensory capacity and are major regulators of bone
remodeling [2]. Osteoclast-mediated bone resorption releases
growth factors from the bone matrix [3, 4] that increase
osteoblast progenitor number, recruitment, differentiation,
and activity. In addition, osteoclasts regulate osteoblasts di-
rectly via cell-cell contact [3, 5] and by secreting additional
factors [6] that increase osteoblast number and/or activity.
Osteoclast number and activity are regulated by receptor
activator of nuclear factor kappa-B ligand (RANKL), a
membrane-bound protein produced by neighboring osteo-
cytes and osteoblasts [7]. Thus, the products of osteoclast
activity play a key role in the complex interactive regulation
of bone remodeling.
With the exception of parathyroid hormone (PTH) and its
analogs, all agents currently used in the treatment of osteopo-
rosis, such as bisphosphonates, selective estrogen receptor
modulators, and the anti-RANKL antibody, act primarily by
decreasing osteoclast-mediated bone resorption [8], allowing
osteoblasts to increase bone mass by filling in the remodeling
space [9, 10]. Furthermore, slower bone remodeling allows
increased bone mineralization, at least for some agents, and
leads to a reduction in cortical porosity [9–12]. However,
inhibition of osteoclast activity also leads to a secondary
reduction in bone formation [8, 13], limiting the ultimate
increase in bone mass.
The mechanism of osteoclast-mediated bone resorption is
well characterized [7]. Osteoclasts attach to the bone surface
and secrete hydrogen ions and proteolytic enzymes into the
remodeling space. The acidic environment dissolves bone
mineral and exposes bone matrix proteins. Cathepsin K
(CatK) is the primary osteoclast-produced protease involved
in the degradation of type I collagen and other bone matrix
proteins [14]; its pH optimum is in the range of the acidic
remodeling space.
Congenital absence of CatK in humans results in
py cnody so s t o s i s , a r a r e a u t o s oma l r e c e s s i v e
osteochondrodysplasia. This disease is characterized not only
by high bonemass but also increased risk of fractures and bone
deformities [15]. Importantly, the increased fragility and bone
deformities are not present in heterozygotes [15]. Targeted
disruption of the CatK gene in mice produced a high bone
mass phenotype [16] while overexpression of CatK increased
bone turnover and decreased trabecular bone volume [17].
The effect of CatK inhibition has been studied in estrogen-
deficient non-human primates and rabbits. In these studies,
CatK inhibitors significantly reduced bone resorption while
relatively preserving bone formation, resulting in both in-
creased BMD and bone strength, in contrast to congenital
absence of CatK [16]. CatK inhibition decreased the removal
of bonematrix protein but did not reduce osteoclast number or
affect other osteoclast activities, such as the production of
osteoblast-stimulating factors [16].
Odanacatib (ODN, MK-0822) is a selective, orally admin-
istered CatK inhibitor. Unlike basic CatK inhibitors, ODN is
neutral, so it does not accumulate in the acidic environment of
lysosomes, which could lead to off-target inhibition of other
cathepsins [18, 19]. ODN is metabolized by CYP3A4, has an
apparent terminal half-life of approximately 40 to 80 h [20,
21], and its absorption is not impaired by food intake [20, 21].
A phase IIb dose-ranging trial and its extensions have
demonstrated progressive dose-dependent increases in BMD
in postmenopausal women with low BMD [22–24]. ODN
substantially reduced biochemical markers of bone resorption.
However, markers of bone formation decreased to a lesser
degree than was previously observed with other anti-
resorptive treatments and returned towards baseline within
2 years, on continued treatment [22–24]. Histomorphometry
of bone biopsies from participants in the phase IIb study
indicated that osteoclast number was maintained [22],
confirming preclinical results [16]. Lack of reduction of serum
TRAP5b levels with ODN treatment in the phase IIb trial
confirmed osteoclast viability. Discontinuation of ODN treat-
ment resulted in increased bone turnover and reduction in
BMD, which returned to baseline within 1 to 2 years [23].
Based on BMD data after 12 months from the phase IIb trial,
ODN 50 mg once weekly was selected as the dosing regimen
for the phase III trial [22].
A prospective study was designed to assess the anti-
fracture efficacy and safety of ODN in postmenopausal wom-
en with osteoporosis. This report describes the design of this
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study and presents the key baseline characteristics of its
participants.
Study design
Overview of study design
The study, odanacatib Protocol 18, was designed by the spon-
sor, Merck & Co. Inc., Whitehouse Station, NJ, USA, in
collaboration with a Scientific Advisory Committee (SAC)
that provided input on the clinical development program.
The study was planned as a multinational, random-
ized, double-blind, event-driven placebo-controlled trial
of approximately 5 years duration and was approved by
governing ethical review committees (ERCs) and insti-
tutional review boards (IRBs). Provision was made for
early termination of the study if criteria for reduction of
fracture risk versus placebo were met in prespecified
interim analyses (see “Statistical methods”).
Study participants were women at least 65 years of age and
postmenopausal for at least 5 years, who were osteoporosis
treatment-naïve or had been exposed to minimal prior osteo-
porosis treatment. Two categories of participants were eligible
(Table 1):
& Women with a prior radiographic vertebral fracture were
required to have a BMD T-score ≤−1.5 at either the
femoral neck (FN) or total hip (TH).
& Those without a prior vertebral fracture were required to
have a BMD T-score ≤−2.5 at the FN or TH, using the
NHANES III 1998 database (reference values are those
for Caucasian young adult women).
In either category, women with prior hip fractures at any
time or clinical fragility fractures within the prior 2 years or
whose BMD T-score was <−4.0 at either the FN or TH were
excluded to minimize individual participant risk, unless they
were unable or unwilling to use available osteoporosis
treatments.
This trial was designed to test the hypotheses that treatment
with ODN 50 mg once weekly reduces the risk of radiograph-
ically detected vertebral, clinical hip, and clinical non-
vertebral fractures (all primary end points) in postmenopausal
women with osteoporosis. Secondary end points included the
incidence of clinical vertebral fractures; change in height;
BMD at the TH, FN, trochanter, lumbar spine (LS), 1/3 radius;
biochemical markers of bone formation and resorption; and
safety and tolerability, including bone histology.
Participants were randomized in a 1:1 ratio to take either
ODN 50mg or matching placebo once weekly, without regard
to food or physical position. They were given 5600 interna-
tional units (IU) of vitamin D3 weekly and calcium
supplements as needed to ensure a total daily calcium intake
of approximately 1200 mg. A dietary calcium questionnaire
was administered at intake and at yearly intervals during the
trial. Following screening and randomization visits, study
visits in the clinic were scheduled every 3 months in the first
year of the study and every 6 months thereafter. Telephone
contact alternated with clinic visits every 3 months after the
first year.
Rationale for study design
This trial was designed with primary fracture end points,
consistent with regulatory requirements for new drugs for
the treatment of postmenopausal osteoporosis. It employed a
placebo control group, consistent with previous and current
registration trials of drugs for that indication. This approach
has been the subject of extensive discussion [25], including a
US FDAAdvisory Committee Meeting [26] which provided a
frame of reference for recent trial design. Placebo-controlled
pivotal trials in osteoporosis were considered acceptable, pro-
vided that appropriate limits are placed on the severity of
disease in those individuals who could otherwise be treated
with available medication. Background treatment with ade-
quate calcium and vitamin D3 intake for all participants was
also regarded as an important consideration. Limits regarding
the range of acceptable BMD and fractures prior to study entry
as well as monitoring for excessive on-study bone density
decreases have been generally consistent in more recently
completed [27] and ongoing [28, 29] phase III trials.
Accordingly, the present study excluded participants
at relatively high risk for fracture, using specific criteria
based on BMD and prior fracture history, and employed
safeguards to protect participant safety. The trial was
overseen by an external data monitoring committee
(DMC) that periodically reviewed unblinded safety data.
BMD was measured yearly and identified participants
with excessive bone loss (EBL) (predefined as >7 %
from baseline at any time at the LS or TH). If the
decrease was confirmed, the participant was then
discontinued from study medication and treated conven-
tionally. Adverse events of interest were referred for
adjudication by panels of experts with relevant scientific
expertise (see section on “Adverse event reporting and
adjudication”).
The study was powered to detect a significant effect
of ODN to reduce the risk of hip fractures. Because of
the safety criteria at enrollment, the baseline individual
hip fracture risk in the study population was limited.
Hence, the sample size estimate was about twice that of
the largest osteoporosis trial. The event-driven design of
the study allowed for some uncertainty in the estimate
of the rate at which participants would experience frac-
ture events.
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Table 1 Inclusion criteria and exclusion criteria
Inclusion criteria
Participant:
1) Is a woman at least 65 years of age
2) Meets one of the following criteria:
Criterion Femoral neck or total hip
BMD




Suitable candidate for available osteoporosis
therapy
A ≤−1.5 ≥−4.0 1 Yes
B ≤−2.5 ≥−4.0 0 Yes
C ≤−1.5 No restriction ≥1 No
D ≤−2.5 No restriction 0 No
3) May not be a suitable candidate for commercially available osteoporosis therapy, e.g., due to contraindication, established intolerance, physician’s
judgment, or participant’s unwillingness
4) Has at least one hip that is evaluable by DXA
5) Postmenopausal for at least 5 years
6) Understands the study procedures, alternative treatments available, and voluntarily agrees to participate by giving written informed consent
7) Is ambulatory
8) Is able to read, understand, and complete questionnaires and diaries
Exclusion criteria
Participant:
1) Has chosen treatment with agents demonstrated to reduce the risk of hip fracture
2) Has prior fragility hip fracture and is a suitable candidate for osteoporosis therapy (i.e., bisphosphonates, strontium ranelate, or PTH)
3) Has experienced a clinical fragility fracture (including a clinical vertebral fracture) within the prior 24 months
4) Had more than one prior vertebral fracture, as defined in inclusion criterion 2 above and is a suitable candidate for osteoporosis therapy
5) Has evidence of a metabolic bone disorder other than osteoporosis
6) Has a history of renal stones and serum calcium, serum 25-hydroxyvitamin D, and serum PTH are not all within normal limits. Serum 25-
hydroxyvitamin D levels below 20 ng/mL (50 nmol/L) were considered abnormal
7) Has active parathyroid disease
8) Has a history of thyroid disease not adequately controlled by medication
9) Has serum creatinine >1.6 mg/dL and is considered to have severe renal insufficiency defined as calculated creatinine clearance ≤29 mL/min2
10) Has received treatment with an agent that has an effect on bone including
Bisphosphonates
• Use of any oral bisphosphonate in the 6 months prior to screening
• Use of any oral bisphosphonate for more than 3 months within the prior 2 years
• Lifetime use of more than 6 months total; any lifetime use of IV zoledronate3
Within the prior 12 months, use of
• PTH (1–34 or 1–84)
Within the prior 6 months, use of
• Estrogen with or without progestin
• Raloxifene or other SERM, tibolone or an aromatase inhibitor
• Subcutaneous calcitonin4
Within the prior 6 months, use for more than 2 weeks of
• Systemic glucocorticoids (≥5 mg/day of prednisone or equivalent)
• Cyclosporin
Within the prior 3 months, use of
• Activated vitamin D (e.g., alphacalcidol)
At any time, use of
• Any anabolic steroid
• Fluoride treatment at a dose greater than 1 mg/day for more than 2 weeks
• Growth hormone
• Any cathepsin K inhibitor
• RANK ligand inhibitor
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Recruitment, follow-up, and assessments
Recruitment
Informed consent was obtained from all study participants
before any study procedure was performed. It was required
that a qualified physician discuss alternative treatment options
with each participant. At the request of a regulatory agency,
participant enrollment was conducted in two phases to allow
expansion of the safety experience for ODN before the entire
study was enrolled.
The first phase (the lead cohort) randomized 1499 partici-
pants between November 2007 and March 2008. After
9 months of treatment, the lead cohort safety data were eval-
uated by the DMC (see below for details), which recommend-
ed that the enrollment of the remainder of the participants (the
main cohort) could commence. The enrollment of 15,214
participants in the main cohort occurred from January to
November 2009 (Fig. 1). Thus, a total of 16,713 women were
recruited at 387 investigational sites in 40 countries.
At one investigative site, sponsor inspections identified
issues that materially affected data integrity. The sponsor
determined that these findings warranted exclusion of that
site’s data from the primary efficacy and safety analyses and
informed the US FDA. (All data, including those excluded
from the primary analyses, are to be provided in regulatory
submissions). Data from 483 participants were affected, in-
cluding 111 in the lead cohort. An additional 159 participants
were excluded from the analysis because they never took
study medication (N=156) or because they had been assigned
duplicate allocation numbers (N=3). Thus, the number of
evaluable participants was 16,071, including 1373 in the lead
cohort.
Randomization and stratification
Randomization was performed by a computer-generated allo-
cation schedule using an interactive voice recognition system
(IVRS), which randomly assigned each participant to ODN or
placebo. Participants were assigned to one of two strata,
according to vertebral fracture status. Participants without
prior vertebral fracture were assigned to the no-prior-verte-
bral-fracture stratum. At least two thirds of the participants in
the no-prior-fracture stratum were required to be at least
70 years of age. Participants with a prior vertebral fracture
were assigned to the prior-vertebral fracture stratum. IVRS
was used to keep track of enrollment and the number of
participants randomized into each stratum and to close a
stratum as needed. IVRS was also available for emergency
unblinding if this were required for an individual participant’s
safety.
Blinding
Study participants, investigators and their staff, and sponsor’s
personnel were blinded to treatment allocation. Only the
DMC and support statistical personnel (see below) had access
to unblinded data. Selected adverse events (AEs) and changes
in selected laboratory results were provided to the FDA in an
Table 1 (continued)
• Strontium-containing products
• Protease inhibitors for HIV treatment
Current use
• Chemotherapy or heparin
• Vitamin A >10,000IU daily
• Vitamin D supplement >1200IU daily and is unwilling to limit vitamin D supplement
• Anti-seizure medication and indices of calcium metabolism are not within normal limits
• Systemically administered azole antifungals
11) Has a daily calcium intake of <1200mg and is unwilling to take study-prescribed calcium supplements
12) Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study or
interfere with the participant’s participation for the full duration of the study
13) Has a history of malignancy ≤5years prior to signing informed consent
14) Is >80years old and has a history of recurrent falls (≥2 falls in 1year)
15) Is currently participating in a study with an investigational compound or device
16) Is a user of recreational or illicit drugs or has a recent history (within the last year) of drug or alcohol abuse or dependence
17) Demonstrates hepatic dysfunction defined as
Elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×upper limit of normal (ULN) and
Elevation in total bilirubin >2×upper limit of normal (ULN)
18) Is considered to be at excessive risk of incident fracture according to local Ethics Committee and/or local regulatory agency
1Defined as anterior, mid, or posterior height loss of >20 %
2Using the Cockcroft-Gault formula for creatinine clearance
3One dose of IV pamidronate or IV ibandronate more than 1 year prior to screening is allowed
4Use of intranasal calcitonin either prior to or during the study is permitted
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unblinded fashion, while maintaining the blind for study
participants, investigators, and other sponsor personnel.
Assessments
Prior to randomization, a medical history, including assess-
ment of concomitant medications, physical examination,
BMD measurements by dual-energy X-ray absorptiometry
(DXA), lateral spine radiographs for vertebral fracture assess-
ment, laboratory assessments, and review of inclusion and
exclusion criteria were performed. Follow-up assessments
were conducted as follows: limited physical examination in-
cluding vital signs and laboratory assessment every 3 months
during the first year, and then every 6 months. Drug account-
ing and AE assessments were performed at every visit. Lateral
spine radiographs were performed at baseline, month 6, month
12, and every 12 months thereafter. BMD was measured at
baseline and yearly thereafter. Height was assessed using a
calibrated stadiometer at baseline and yearly.
Radiographic vertebral fracture assessment
Spine radiographs were evaluated at a central site (Synarc,
Newark, CA, USA). Screening spine radiographs were eval-
uated for the presence or absence of a vertebral fracture using
the Genant semi-quantitative scale [30]. Only vertebral
fractures in the region T4 to L4 were counted. Participants
with Genant grade 1–3 deformities (mild, moderate, or severe)
were included in the stratum with prior vertebral fracture.
Follow-up radiographs were evaluated to detect incident
(new or worsening) vertebral fractures, first using the Genant
semi-quantitative method and upon detection of a fracture,
morphometric analysis for confirmation.
BMD measurements
BMD was measured using Lunar, Hologic, or Norland densi-
tometers, at femoral sites (total hip, femoral neck, and tro-
chanter) and the lumbar spine in all participants and at the 1/3
radius and total body (excluding head) in a randomly selected
10 % subset of participants from sites with appropriate equip-
ment. The central DXA assessment site (Synarc, Newark, CA,
USA) performed QC assessment of all DXA scanners and
analysis of all DXA scans.
Laboratory assessments
Serum chemistry, including serum calcium (total and
corrected for serum albumin), phosphate, magnesium, liver
function tests, hematology, and urinalysis were performed at
baseline and follow-up. Serum 25-hydroxyvitamin D, PTH,
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Fig. 1 CONSORT Diagram. The
asterisk indicates 642 randomized
participants were excluded from
all analyses due to the following
reasons: allocation of duplicate
allocation numbers (n=3), took
no study medication (n=156), or
because their study site was
closed and excluded from all
efficacy and safety data analyses
(n=483). The primary all-
patients-as-treated analysis will
be based on 16,071 participants,
of whom 1373 were in the lead
cohort. The dagger indicates 245
of the 8256 patients were found to
be ineligible because they had
experienced excessive bone loss
detected at the transitional visit
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the same subset of participants who underwent 1/3 radius and
total body DXA measurements as described above. The fol-
lowing bone turnover markers were measured by Synarc Labs
(Lyon, France) on specimens obtained in the fasting state:
urinary N-telopeptides of type I collagen (NTx, VITROS
ECL/ECIQ, Ortho Clinical Diagnostics, Rochester NY,
USA), serum C-telopeptides of type I collagen (CTx,
Elecsys-CrossLaps/serum ECL, Roche Diagnostics, Mann-
heim Germany), serum procollagen type 1 N-terminal
propeptide (P1NP, Elecsys/serum ECL kit, Roche Diagnos-
tics, Mannheim Germany), and serum bone-specific alkaline
phosphatase (BSAP, Access Ostase, Beckman Coulter, Brea,
CA, USA). Fasting urine and serum specimens were archived
from each participant at all visits.
Bone biopsy
Transilial bone biopsy was an optional procedure in partici-
pants who provided a separate consent. A total of 341 biopsies
were obtained from 272 participants. Forty biopsies were
obtained at baseline and 301 after 12, 24, or 36 months.
Double-fluorochrome labeling with either tetracycline or
demeclocycline was used to assess bone formation. The biop-
sy specimens were analyzed at the Osteoporosis Research
Center, Creighton University, Omaha, NE, USA using
histomorphometric and micro-CT techniques [31]. Biopsy
examiners were blinded to participant identity, treatment allo-
cation and time-point. Histomorphometric variables were
measured, calculated, and expressed according to the guide-
lines of the American Society of Bone and Mineral research
(ASBMR) Nomenclature Committee [32].
Clinical fracture end point assessment
Clinical vertebral and non-vertebral fractures were key end
points of the study. Therefore, all fractures reported as AEs
were adjudicated by a clinical adjudication committee (CAC)
of radiologists at the central evaluation site (Synarc, Newark,
CA, USA). Based on clinical history and radiographs, the
CAC determined whether a fracture was confirmed; its ana-
tomic location and laterality; and whether it was osteoporotic
or due to trauma, stress, or other pathology (neoplasm or
infection). The adjudication involved a two-round process.
A unanimous vote from three CAC members, chosen at
random from a panel of four, who reviewed the participant
data independently via internet-based software (Virtual Panel
System, Parexel International, Waltham, MA, USA), was
required to complete the adjudication during the first review.
If the vote were not unanimous, then all four CAC members
would review the case in a conference (second review) and a
three-fourths majority vote was required to confirm the frac-
ture. The CAC could also determine that insufficient data were
available to complete the adjudication of a fracture event.
Fractures that were possible atypical femoral shaft fracture
events were adjudicated according to the ASBMR criteria and
were always discussed by four CAC members in a one-round
process [33, 34].
Adverse event reporting and adjudication
At each clinic or telephone visit, participants were queried
about interval AEs and the responses recorded. Participants
were also instructed to report any serious AEs such as hospi-
talization to the investigational sites immediately. Changes in
laboratory parameters were evaluated by the investigators to
determine whether they were clinically significant and report-
able as AEs.
Several categories of specific AEs were designated for
adjudication by external CAC committees (cardiovascular,
cerebrovascular, dental, skin thickening and hardening, de-
layed fracture union, and serious respiratory events) to con-
firm their occurrence and specific attributes. These AEs, ra-
tionale for their adjudication, data collected for the adjudica-
tion, and specific attributes to be adjudicated are summarized
in Table 2. These AEs were adjudicated in a two-round
process similar to that previously described for fractures.
Adjudication of all AEs was managed by a central site
(Parexel International, Waltham, MA, USA), which was re-
sponsible for collection of all clinical data, electronic distri-
bution to the CAC members, coordination of CAC member
conferences, collation of adjudication results, and final data
transfer to the sponsor.
Discontinuation criteria
Participants were discontinued from blinded study drug if the
investigator considered that the risk outweighed the benefit of
continued participation on blinded therapy for an individual
participant. Additionally, participants were discontinued from
blinded study drug if they experienced excessive bone loss, as
described above; initiated treatment with a strong CYP3A4
inducer (e.g., carbamazepine, phenytoin, rifampin, St. John’s
wort) for longer than 6 months; commenced treatment with
other drugs for osteoporosis; or had persistent elevations in
serum transaminases or bilirubin. The sponsor provided
alendronate 70 mg OW to patients who were discontinued
from study drug, although other treatment options were not
prohibited. Participants were followed for outcome and safety
monitoring through the end of the base trial even if blinded
study therapy was discontinued.
Data monitoring committee
The ODN clinical development program, including this frac-
ture outcome study, was monitored by a DMC, which
consisted of seven experts not involved in the conduct of the
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study, including six physicians, five of whom were experts in
osteoporosis with subspecialty expertise in endocrinology,
rheumatology, geriatrics, and epidemiology; a dermatologist;
and a non-physician statistician. The DMC was supported by
a statistician and statistical programmer from the sponsor.
Only the DMC and their support statistical personnel had
access to unblinded data from the trial, with the exception that
safety data were provided to the FDA in an unblinded fashion
as described above. Since September 2007, the DMC has met
at intervals of approximately 4 months to review safety data
from the ODN program, including data from this trial, and to
make recommendations on the conduct of the trials. The DMC
was also responsible for the review of the two planned interim
efficacy analyses and had the option of recommending to the
sponsor to terminate the study early due to futility or due to
robust efficacy and a favorable benefit-risk profile of the drug.
Ancillary studies
Population pharmacokinetics study
Three specimens were collected from each participant in the
lead cohort for the measurement of plasma ODN levels to
confirm findings from phase I. Information was collected with
regard to timing of the collection and last dose of ODN and
characteristics of the meal prior to last dose.
Special imaging sub-study
A sub-study of 164 participants investigated the effect of
ODN on volumetric BMD of the hip and spine and, specifi-
cally, on the trabecular and cortical components at each site,
using quantitative computed tomography (QCT, instruments
from GE Medical Systems, Phillips, Siemens, and Toshiba).
High-resolution peripheral QCT (Scanco Xtreme CT) was
employed to investigate the effect of ODN on bone
microarchitecture at the distal radius and distal tibia in some
of these participants. Imaging procedures were performed
yearly, and all participants in this study had biochemical
markers of bone turnover measured at these time-points. Only
participants in this sub-study were asked to consent to optional
bone biopsies at baseline and 12 months.
Sarcopenia end point sub-study
This was an exploratory sub-study of 556 participants de-
signed to identify molecular signatures of sarcopenia using
DNA and RNA biomarkers in the blood and to examine
changes in appendicular lean body mass, measured by total
body DXA, and physical function, measured by the Short
Physical Performance Battery (SPPB).
Participation in the special imaging and sarcopenia sub-
studies was optional and involved separate consent forms
from those used for the main study.
Statistical methods
Data analysis
The primary end points of the study were the first morpho-
metrically confirmed vertebral fracture per participant, first
osteoporotic clinical hip fracture confirmed by adjudication,
and first osteoporotic clinical non-vertebral fracture confirmed
by adjudication. There was a hierarchical order from morpho-
metric vertebral fractures (the first primary end point) to the
other two end points; there was no order set between hip and
non-vertebral fractures.
The all-patients-as-treated population (n=16,071) was
used for safety analyses and included all participants who took
at least one dose of study medication and had at least one
follow-up visit with the exclusions noted above. Treatment
groups were compared using the Miettinen and Nurminen
method [35], adjusted for differential follow-up period, for
prespecified sets of AEs of clinical relevance.
The full-analysis population was used for efficacy analy-
ses. With the exclusions noted above in “Recruitment,” it
included all randomized participants who took at least one
dose of study medication regardless of protocol violation,
adherence to study medication, or early discontinuation from
the study and had at least one follow-up efficacy assessment.
The follow-up period was from randomization to study termi-
nation. The number of patients included in the efficacy anal-
yses varied according to the number and timing of observa-
tions for each end point.
Morphometrically confirmed vertebral fracture data were
evaluated with a generalized linear model for binary data with
the complementary log-log transformation of the probability
of an event up to the time-point. Clinical hip and non-vertebral
fracture data were analyzed by time-to-event methods using
Kaplan-Meier estimates and a Cox proportional hazards
model.
A step-down procedure [36] controlled for increased false
positive error risk due to multiple primary end points, in the
order of (1) morphometric vertebral fractures and (2) clinical
hip and clinical non-vertebral fractures. Significance of the
morphometric vertebral fracture primary end point was re-
quired before testing the other two primary end points. The
Hochberg procedure was used to control for the multiplicity of
fracture end points [37].
For BMD end points, treatments were compared using a
longitudinal model with terms for treatment, stratum, geo-
graphic region, and treatment-time interaction on the percent
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change from baseline. Log-transformed fractional change
from baseline in biochemical markers was analyzed using
the same model as BMD. Yearly rate of height loss was
analyzed using a longitudinal model. Testing for secondary
end points was performed only if significance for the first
primary end point (morphometric vertebral fractures) was
obtained. For the purpose of addressing the issue of multiplic-
ity adjustment, three groups were considered: (1) BMD mea-
sures, (2) biochemical markers of bone resorption, and (3)
clinical vertebral fractures and height. Hochberg multiplicity
adjustment procedure was used within each of three groups.
No adjustment for multiplicity between the three groups was
applied.
Sample size considerations
To provide at least 90% statistical power to demonstrate a risk
reduction of vertebral fracture by 50 %, hip fracture by 35 %,
or non-vertebral fracture by 20 %, the estimated required
numbers of participants with these fractures were 114, 237,
and 824, respectively. Sample size estimates were based on
the fracture incidence in the alendronate Fracture Intervention
Trial (FIT) and assumed that approximately 25 % of partici-
pants would have a prior radiographic vertebral fracture [38].
The estimated enrollment requirement was based on hip frac-
ture projections, since these events are least frequent. On this
basis, randomization of approximately 16,000 participants
was planned.
Interim analyses
Two interim analyses were planned to be conducted, when
approximately 70 and 85 % of the targeted 237 participants
had experienced an osteoporotic hip fracture event. To adjust
for multiplicity, an alpha spending function was used for the
interim and final analyses, such that p values of approximately
0.007, 0.018, and 0.046 were required for the first and second
interim and final analyses, respectively.
Planned subgroup analyses
Prespecified subgroup analyses for the primary efficacy end
points included age (<70 and ≥70 years), race, prior radio-
graphic vertebral fracture, baseline BMD T-score tertiles,
baseline biochemical bone turnover marker tertiles, geograph-
ic region, baseline renal function, bisphosphonate intolerance,
vitamin D status, BMI tertiles, and participation in the lead or
main cohort. Subgroup analyses including age, race, bisphos-
phonate intolerance, and ability or willingness to be treated
with available osteoporosis therapies were conducted for the
following safety end points: combined clinical as well as
combined laboratory AEs and skin disorders and dental dis-
orders reported by investigators as AEs.
Participant baseline characteristics
The numbers of participants screened and enrolled are shown
in Fig. 1 and their geographical distribution in Table 3. Base-
line characteristics are shown in Table 4. The average age of
the study population was 72.8 years, 56.5% of the participants
were Caucasian, and the average number of years since men-
opause was 25.3. Baseline vertebral fractures were identified
in 46.5 % of subjects.
Extension study
In recent years, questions have arisen about the benefits and
risks of long-term treatment with osteoporosis medications
[39]. At the initiation of the current trial, it was anticipated
that up to 5 years of blinded therapy might be required to
evaluate its end points, and this duration was specified in the
protocol and participant consent forms that were approved by
ERCs and IRBs. Provision was made for early termination of
the study if significant reductions in fracture risk were dem-
onstrated in either preplanned interim analysis. In order to
ensure collection of long-term data, an extension study was
planned in which study participants would continue in a
blinded fashion on their randomized treatment until they








Asia 110 (28.4) 3151 (18.9)
Latin America 62 (16.0) 5442 (32.6)
Europe/US/others 215 (55.6) 8120 (48.6)
Total 387 16,7131
Special imaging sub-study
South Africa 3 (30.0) 61 (37.2)
Europe/US/others 7 (70.0) 103 (62.8)
Total 10 164
Sarcopenia end point sub-study
Asia 3 (8.8) 73 (13.1)
Latin America 8 (23.5) 263 (47.3)
Europe/US/others 23 (67.6) 220 (39.6)
Total 34 556
Bone biopsy
Asia 2 (7.7) 6 (2.2)
Latin America 9 (34.6) 51 (18.6)
Europe/US/others 15 (57.7) 215 (79.2)
Total 26 272
1 Three randomized participants were subsequently excluded due to as-
signment of duplicate allocation numbers
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reached the originally anticipated total of 5 years, after which
participants would transition to open-label ODN.
Current status
On July 11, 2012, the sponsor announced the decision to
terminate the base study early based on the DMC recommen-
dation following its review of the first interim analysis. That
analysis was performed after approximately 70% of the target
hip fracture events (158 participants with an incident osteo-
porotic hip fracture) had occurred. The DMC based its rec-
ommendation on the observation of robust efficacy and a
favorable benefit/risk profile of ODN relative to placebo.
The DMC also recommended that additional safety data be
obtained in the previously planned blinded extension study.
Following this recommendation, study participants attended a
final base study visit and, if eligible, were asked to consent to
enter the extension study. The base study was closed out
between August and November, 2012, and will form the basis
for the primary comparative efficacy and safety analyses.
There were important differences between the base and
extension studies in study design and conduct. In the base
study, all participants who discontinued study medication
were allowed to remain in the trial and be followed unless
they withdrew consent. However, participants who were no
longer taking study medication at the time of their final base
study visit were not eligible to enter the extension. Of 16,713
women initially randomized in the base study, 8256 entered
the extension study. Of the approximately 8000 women who
did not enter the extension, most were ineligible because they
had not completed the base study on therapy or because the
investigational site did not participate in this phase of the trial.
A total of 1281 women experienced excessive bone loss
during the base study. Most of them discontinued prior to
entering the extension. However, 245 women were excluded
shortly after entering the extension because of excessive bone
loss detected at the transitional visit.
The loss of nearly half the original participants created a
substantial likelihood that the extension population would differ
materially from the original trial population. Participants who
experienced excessive bone loss during the base study were
discontinued from study drug and were therefore ineligible to
enter the study extension. It would be expected that a greater
number of participants from the placebo arm were discontinued
due to excessive bone loss. Thus, although it was blinded, the
extension cannot be presumed to have maintained the
randomization.
As osteoporosis requires long-term treatment, extension stud-
ies of active treatment, with or without a withdrawal arm, have
become customary. Prior trials have not generally extended the
randomized placebo phase beyond the primary end point. In the
report of the 10-year extended phase III alendronate studies, the
authors used the expected effect of aging on fracture rates in the
original placebo group in order to provide context for interpreta-
tion of the rates observed on active treatment in the latter years
[40]. A more sophisticated approach, taking more variables into
account, was subsequently developed and validated using data
from the alendronate FIT trial [41]. This “virtual twin”model has
been used in the analyses of data from the long-term extension of
the denosumab phase III trial for which a placebo comparison
was no longer available [42]. A similar model will be developed
from the placebo group in theODNbase study. Thismay provide
useful information about expected fracture rates and other effi-
cacy and safety results for a virtual long-term placebo group with
characteristics matching the active treatment population.




Age (years), mean (SD) 72.8 (5.3)





Black/African American 261 (1.6)
Native American 185 (1.2)
Pacific Islander 2 (0.001)
BMD T-score, mean (SD)
Lumbar spine −2.7 (1.2)
Total hip −2.4 (0.7)
Femoral neck −2.7 (0.5)
Trochanter −2.3 (0.8)
Bone turnover markers, mean (SD)1
uNTX/Cr (nmol/mmol Cr) 47.4 (37.4)
sCTX (ng/mL) 0.44 (0.22)
sBSAP (ng/mL) 15.78 (6.50)
sP1NP (ng/mL) 58.62 (28.81)





Years since menopause, mean (SD) 25.3 (7.7)
Prior radiographically assessed vertebral fracture, n (%)2 7446 (46.4)
Mild fracture (Genant grade 1) 4414 (59.3)
Moderate fracture (Genant grade 2) 1858 (25.0)
Severe fracture (Genant grade 3) 1174 (15.8)
Unreliable or missing data 36
1Measured in 10 % subset of participants
2 Grade of fracture was determined based on the worst grade per partic-
ipant over all available scans up to 7 days after first study dose
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Summary
Inhibition of cathepsin K is an attractive pharmacological
approach with therapeutic potential in osteoporosis. Preclini-
cal and initial clinical data provided a strong rationale for the
use of ODN in the treatment of osteoporosis, and the phase IIb
trial identified 50 mg once weekly as a dose regimen that is
effective on BMD end points. The ODN phase III fracture trial
was designed to rigorously investigate the efficacy and safety
of this selective CatK inhibitor in the treatment of osteoporosis
in postmenopausal women.
This placebo-controlled study excluded participants who
were at excessively high individual risk of fracture and in-
cluded safeguards to ensure participant safety. In addition to
fractures, the study evaluated multiple end points that not only
provide information about ODN but may also help expand our
knowledge of osteoporosis. An interim analysis demonstrated
sufficiently robust anti-fracture efficacy and favorable benefit-
risk profile to warrant early termination of the base study. The
blinded extension study enrolled more than 8000 continuing
participants and will provide additional data concerning the
longer-term safety and efficacy of ODN.
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